Comparing two maintenance treatments for ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study compares taking tofacitinib alone versus combining it with mesalamine to keep ulcerative colitis under control. If you are currently in remission, this trial may help find the best way to prevent flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of ulcerative colitis through endoscopy and biopsy.
- You have been in remission (no active symptoms) for at least 3 months.
- You are currently taking both tofacitinib and mesalamine.
- You are not pregnant, planning to become pregnant in the next two years, or breastfeeding.
- You do not have certain other bowel conditions, like Crohn's disease or microscopic colitis.
- You have not had blood clots, heart failure, or a heart attack in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
This trial tests whether adding febuxostat, a medicine usually used for gout, can help reduce inflammation in people with mild to moderate ulcerative colitis who are already taking mesalamine. It aims to see if this combination is safe and effective.
This trial tests new therapies for people with a severe UC flare that hasn't improved after 5 days of high-dose steroids. It aims to find more effective options to control symptoms and avoid hospitalization.
This trial tests whether giving two medicines together (infliximab and tofacitinib) is safe and effective for people hospitalized with a severe flare of ulcerative colitis. The goal is to see if the combination works better than standard care to help you recover faster.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.